RU2008108216A - Фармацевтические дозированные формы и составы, содержащие лекозотан - Google Patents
Фармацевтические дозированные формы и составы, содержащие лекозотан Download PDFInfo
- Publication number
- RU2008108216A RU2008108216A RU2008108216/14A RU2008108216A RU2008108216A RU 2008108216 A RU2008108216 A RU 2008108216A RU 2008108216/14 A RU2008108216/14 A RU 2008108216/14A RU 2008108216 A RU2008108216 A RU 2008108216A RU 2008108216 A RU2008108216 A RU 2008108216A
- Authority
- RU
- Russia
- Prior art keywords
- max
- lecosotan
- patients
- patient
- dosage form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 10
- 238000000034 method Methods 0.000 claims abstract 68
- 239000006186 oral dosage form Substances 0.000 claims abstract 47
- 230000036470 plasma concentration Effects 0.000 claims abstract 26
- 239000003937 drug carrier Substances 0.000 claims abstract 23
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 18
- 230000002411 adverse Effects 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 17
- 239000002552 dosage form Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 10
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 4
- 229950007396 lecozotan Drugs 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 210000005069 ears Anatomy 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000035824 paresthesia Diseases 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71541705P | 2005-09-09 | 2005-09-09 | |
| US60/715,417 | 2005-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008108216A true RU2008108216A (ru) | 2009-10-20 |
Family
ID=37836444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108216/14A RU2008108216A (ru) | 2005-09-09 | 2006-09-06 | Фармацевтические дозированные формы и составы, содержащие лекозотан |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1928863A2 (https=) |
| JP (1) | JP2009507850A (https=) |
| KR (1) | KR20080043855A (https=) |
| CN (1) | CN101258146A (https=) |
| AR (1) | AR058033A1 (https=) |
| AU (1) | AU2006287543A1 (https=) |
| BR (1) | BRPI0615771A2 (https=) |
| CA (1) | CA2620491A1 (https=) |
| CR (1) | CR9800A (https=) |
| EC (1) | ECSP088236A (https=) |
| GT (1) | GT200600403A (https=) |
| IL (1) | IL189827A0 (https=) |
| NO (1) | NO20081100L (https=) |
| PE (1) | PE20070334A1 (https=) |
| RU (1) | RU2008108216A (https=) |
| TW (1) | TW200800198A (https=) |
| WO (1) | WO2007030589A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| JP2009500425A (ja) | 2005-07-06 | 2009-01-08 | セプラコア インコーポレーテッド | エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 |
| JP2012526832A (ja) * | 2009-05-13 | 2012-11-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE361060T1 (de) * | 2000-09-29 | 2007-05-15 | Solvay Pharm Bv | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung |
| GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| TW200700413A (en) * | 2005-03-01 | 2007-01-01 | Wyeth Corp | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
-
2006
- 2006-09-06 AR ARP060103880A patent/AR058033A1/es unknown
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/pt not_active Application Discontinuation
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/ko not_active Withdrawn
- 2006-09-06 TW TW095132852A patent/TW200800198A/zh unknown
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/ru not_active Application Discontinuation
- 2006-09-06 GT GT200600403A patent/GT200600403A/es unknown
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/es not_active Application Discontinuation
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en not_active Ceased
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/ja not_active Withdrawn
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/zh active Pending
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/no not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/es unknown
- 2008-03-07 CR CR9800A patent/CR9800A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL189827A0 (en) | 2008-11-03 |
| TW200800198A (en) | 2008-01-01 |
| PE20070334A1 (es) | 2007-05-08 |
| KR20080043855A (ko) | 2008-05-19 |
| NO20081100L (no) | 2008-06-03 |
| WO2007030589A3 (en) | 2007-11-01 |
| AR058033A1 (es) | 2008-01-23 |
| BRPI0615771A2 (pt) | 2011-05-24 |
| GT200600403A (es) | 2007-09-19 |
| EP1928863A2 (en) | 2008-06-11 |
| WO2007030589A2 (en) | 2007-03-15 |
| AU2006287543A1 (en) | 2007-03-15 |
| CA2620491A1 (en) | 2007-03-15 |
| CN101258146A (zh) | 2008-09-03 |
| JP2009507850A (ja) | 2009-02-26 |
| CR9800A (es) | 2008-04-28 |
| ECSP088236A (es) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| US8772309B2 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
| US20080096800A1 (en) | Rapid mucosal gel or film insulin compositions | |
| US20080085298A1 (en) | Rapid Mucosal Gel or Film Insulin Compositions | |
| US12016951B2 (en) | Edaravone pharmaceutical composition | |
| PT2059260E (pt) | Composições farmacêuticas compreendendo hgh para distribuição oral | |
| TWI763632B (zh) | 用於重症治療時之鎮靜方法及非口服調配物 | |
| CA2814057A1 (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2010538066A5 (https=) | ||
| BR112013014642A2 (pt) | produto farmacêutico, kit, uso, produtos, métodos e usos inovadores | |
| CN101522185A (zh) | 抗抑郁剂 | |
| US20110257149A1 (en) | Formulation for oral transmucosal administration of lipid-lowering drugs | |
| US20210128507A1 (en) | Formulation for use in a method of treatment of pain | |
| US12533342B2 (en) | Methods of treating bacterial infections | |
| KR100709528B1 (ko) | 혈당콘트롤용 의약조성물 | |
| RU2008108216A (ru) | Фармацевтические дозированные формы и составы, содержащие лекозотан | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| US20060167100A1 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| CN108430581A (zh) | 用于利扎曲普坦的药物组合物 | |
| RU2008114051A (ru) | Дюрантная лекарственная форма, содержащая 3-(2-диметиламинометилциклогексил)фенол | |
| JP2009507850A5 (https=) | ||
| US20230028539A1 (en) | Pharmaceutical composition, complementary kit and application thereof | |
| US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
| MX2015003810A (es) | Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20091012 |